论文部分内容阅读
目的观察EPO治疗肿瘤相关性贫血对乳腺癌患者P-APR血浆VEGF的影响。方法选取乳腺癌患者102例诊断为贫血治疗前及经EPO治疗后14 d、30 d外周静脉血,测定P-APR血浆VEGF含量并进行对比。结果治疗前及治疗后14 d、30 d P-APR血浆VEGF含量呈逐渐下降趋势,治疗后14 d VEGF含量低于治疗前,二者比较差异有统计学意义(t=2.61,P<0.01),治疗后14 d与治疗后30 d VEGF含量比较差异无统计学意义(t=1.43,P>0.05)。结论 EPO治疗可抑制VEGF,不会促进肿瘤新生血管生成。
Objective To observe the effect of EPO on tumor-associated anemia in patients with breast cancer and P-APR plasma VEGF. Methods A total of 102 patients with breast cancer who were diagnosed as peripheral venous blood before and after 14 days and 30 days of EPO treatment were enrolled in this study. Plasma VEGF levels in P-APR were measured and compared. Results The plasma VEGF levels of P-APR decreased gradually before treatment and 14 days and 30 days after treatment. The levels of VEGF in 14 days and 14 days after treatment were significantly lower than those before treatment (t = 2.61, P <0.01) There was no significant difference in VEGF levels between the 14th day and the 30th day after treatment (t = 1.43, P> 0.05). Conclusion EPO treatment can inhibit VEGF, does not promote tumor angiogenesis.